8 June - 9 June 2022

Targeting protein degradation 3 – from discovery to the clinic

Organised by:

SCI's Fine Chemicals Group

SCI, London, UK

The booking system is currently unavailable. Please check back in 24 hours or contact conferences@soci.org.


In recent years, scientists have discovered a new class of molecules which are able to exert control over the degradation of proteins within cells and achieve unique pharmacological effects.  This exciting field of drug discovery has rapidly matured and the first candidate molecules are now being tested in clinical trials.  

For the third conference of this series, we will bring together an exciting line up of academics and industrial speakers.  They will share their cutting-edge science in the field of protein degradation covering a range of topics from understanding the underlying biological processes involved to delivering degraders into the clinic.

Call for posters

An abstract of maximum one A4 page or 300 words indicating title and authors should be sent to conferences@soci.org by Friday 29 April with the subject line “Targeting protein degradation 3 – abstract submission”. Please use the template attached here.


This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly advancing field. It is targeted at academic and industrial scientists engaged in all aspects of research into protein degradation and those interested in broadening their knowledge in this field of drug discovery.

This event is being held back to back with "What's new in immunotherapies 2022".


Afjal Miah

Alice Harnden

Institute of Cancer Research

Alice Harnden is a medicinal chemist at the Institute of Cancer Research, London. She works on projects within the team of Professor Swen Hoelder seeking to discover new cancer treatments. She gain her undergraduate degree at Oxford University and completed her PhD at Durham University in 2019.

Andrew Leach

Andrew Leach is Head of Chemical Biology and Head of Industry Partnerships at the European Bioinformatics Institute (EBI). At the EBI he is responsible for a number of widely-used resources including ChEMBL, SureChEMBL, UniChem and ChEBI. His group is also involved in various international collaborations and consortia including Illuminating the Druggable Genome, Open Targets and EUbOPEN. His industry team works with the many commercial organisations and companies that make extensive use of the EBI's resources. He joined the EBI from GlaxoSmithKline, where over more than 20 years he was involved in the development and application of new platform capabilities for drug discovery in areas including computational chemistry and cheminformatics, fragment-based drug discovery, cardiovascular safety, proteomics and biological mass spectrometry. He also contributed to therapeutic projects and led GSK’s early Discovery portfolios against protease, ion channel and epigenetic targets.

Daniel Glynn

Elisabetta Chiarparin

Fleur Ferguson

Ian Churcher

James Hodgkinson

University of Leicester

James Hodgkinson is a lecturer in Organic Chemistry and Chemical Biology at the Leicester Institute of Structural and Chemical Biology (LISCB) and School of Chemistry, University of Leicester. James completed his undergraduate degree in Chemistry at Queens University Belfast with a year in industry at GlaxoSmithKline and went on to complete his doctoral studies under the joint supervision of Professor David Spring (Department of Chemistry) and Dr Martin Welch (Department of Biochemistry), University of Cambridge. After a Junior Research Fellowship at Trinity College, Cambridge James was appointed to Lecturer at the University of Leicester in 2016. His current research interests are in the design and synthesis of heterobifunctional molecules to modulate Class-I Histone Deacetylase (HDAC) enzymes implicated in haematological cancers and other diseases, as well as chemical probes to aid structural studies of the protein-protein interactions within Class-I HDAC corepressor complexes.

Kristin Riching

Matt Weiss

Oskar hoff

Celeris Therapeutics

Oskar leads our efforts in medicinal chemistry at Celeris Therapeutics. He works closely with our technology group to develop computation methods for the design of proximity-inducing compounds (PIC™) and validates PICs ex silico. Oskar holds a DPhil in organic chemistry from the University of Oxford, UK. Under the supervision of Prof. Donohoe, he worked on the total synthesis of marine furanocembranoidal natural products. At Hoffmann-La Roche in Basel, Switzerland, he worked in the department of small molecule process development. At the Ferrier Research Institute in Wellington, New Zealand, Oskar designed and synthesized enzyme inhibitors as a visiting researcher.

Roy Pollock

William Farnaby


8 June

Day 1
Registration and refreshments
Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications
Dr Matt Weiss, Kymera Therapeutics
Discovery and Optimization of Targeted Protein Degradation Therapeutics
Dr Roy Pollock, C4 Therapeutics
Lunch, exhibition and poster session
Pushing boundaries via academic-industry collaborations : From chemical probes to in vivo active degraders
Dr Will Farnaby, University of Dundee
The PROTACTable genome
Dr Andrew Leach, EMBL’s European Bionformatics Institute
Refreshments and poster session
Chemoproteomic approaches to interrogate the degradable kinome
Dr Fleur Fergusson, U.C. San Diego
New protein degrading mechanisms - challenges and opportunities
Ian Churcher, Amphista Therapeutics
Networking reception

Thursday 9 June

Day 2
Welcome and Refreshments
Opening remarks
Degrading Class I Histone Deacetylase Enzymes in a ‘Complex Environment’
James T. Hodgkinson, Leicester Institute of Structural and Chemical Biology
Engineering proximity-inducing compounds (PICs) – a machine learning approach
Oskar Hoff, Celeris Therapeutics
Improved Binding Affinity and Pharmacokinetics Enables Sustained Degradation of BCL6 In Vivo
Alice C. Harnden, Cancer Research UK Cancer Therapeutics Unit
Coffee and poster session
Exploring cellular PROTAC-induced ternary complex formation and degradation outcomes
Kristin Riching, Promega
Bifunctional degraders of BRPF1 that retain the antiproliferative phenotype
Dr Daniel Glynn, Concept Life Sciences (a Malvern Panalytical brand)
Lunch and poster session
Integration of high-throughput PROTAC synthesis and direct to biology assaying for rapidly evaluating targeted protein degradation
Dr Afjal Miah, GlaxoSmithKline
Rational discovery and design of Targeted Protein Degraders
Dr Elisabetta Chiarparin, AstraZeneca
Closing remarks


Venue and Contact


14/15 Belgrave Square

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Before early bird - ends 26 April 2022
SCI Member - £145
Non-member - £220
Student member - £65
After early bird
SCI Member - £195
Non-member - £270
Student member - £85

There is a 10 percent reduction on the registration fee if you register for the What's new in immunotherapies event in addition to this meeting for SCI members and non-members.

Once you have registered for this event, please email conferences@soci.org for a voucher code.

All registrations will automatically receive a confirmation within 24 hours of registering for the event. Should you not receive written confirmation of your booking, please email conferences@soci.org.

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

Booking terms and conditions

CPD Info

SCI Members attending this meeting are able to claim CPD points.

CPD logo 2021-2023


Organising Committee

    Nicola Chessum, SCI / Boehringer Ingelheim
    Martin Lowe, SCI / Exscientia
    Jayshree Mistry, SCI
    Jamie Scott, SCI / AstraZeneca

Exhibition and Sponsorship

For further information and prices, please email conferences@soci.org.